Antibodies to malondialdehyde-acetaldehyde modified low-density lipoprotein in patients with newly diagnosed inflammatory joint disease
- 4 March 2021
- journal article
- research article
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 50 (2) , 113-117
Abstract
Objective:To assess antibodies to malondialdehyde-acetaldehyde-modified low-density lipoprotein (MAA-LDL) in patients with newly diagnosed inflammatory joint disease. Method: Patients with rheumatoid arthritis (RA), spondyloarthritis (SpA), and undifferentiated arthritis (UA), participating in the Northern Savo 2010 Study, were evaluated for metabolic syndrome (MetS), metabolic and inflammatory markers, antibodies to MAA-LDL,Aggregatibacter actinomycetemcomitans, andPorphyromonas gingivalis. Results: Among 135 newly diagnosed untreated patients, of whom 53 (39%) were diagnosed to have RA, 44 (33%) SpA, and 38 (28%) UA, 49%, 30%, and 47%, respectively, had MetS. After adjusting for age and gender, anti-MAA-LDL immunoglobulin (Ig)A (p = 0.009), IgG (p = 0.031), and IgM (p = 0.001) levels differed between the diagnostic categories, but not in patients with MetS present or absent. All antibody classes to MAA-LDL correlated with erythrocyte sedimentation rate (ESR), and IgA and IgG antibodies with high-sensitivity C-reactive protein (hs-CRP). IgA antibodies to MAA-LDL correlated with rheumatoid factor (RF), anti-citrullinated protein antibodies (ACPAs), fasting plasma glucose, IgA antibodies toA. actinomycetemcomitans, and in IgA and IgG antibodies toP. gingivalis. Conclusion: Among various arthritis groups, antibodies to MAA-LDL were most common in RA. Antibodies to modified lipoproteins were associated with inflammation measured by ESR and hs-CRP. IgA antibodies to MAA-LDL correlated with age, antibodies to periodontal bacteria, RF, ACPA, and fasting glucose. Associations between antibodies to MAA-LDL and antibodies to periodontal bacteria, RA-associated antibodies, inflammatory parameters, and plasma glucose already reflect cardiovascular burden in inflammatory joint diseases at diagnosis.Keywords
Funding Information
- Finnish Cultural Foundation, Northern Savo Regional fund (AK, OKS))
- Sigrid Juselius Foundation (SH))
- The Finnish Rheumatism Association (AK, OKS))
- the Finnish Foundation for Cardiovascular Research (SH))
- The Research Committee of the Kuopio University Hospital Catchment Area for the State Research Funding (AK, OKS))
- the Rheumatism Research Foundation (AK, OKS))
This publication has 14 references indexed in Scilit:
- Enrichment of malondialdehyde–acetaldehyde antibody in the rheumatoid arthritis jointRheumatology, 2017
- Aldehyde-modified proteins as mediators of early inflammation in atherosclerotic diseaseFree Radical Biology and Medicine, 2015
- Malondialdehyde‐Acetaldehyde Adducts and Anti–Malondialdehyde‐Acetaldehyde Antibodies in Rheumatoid ArthritisArthritis & Rheumatology, 2014
- Plasma IgA antibody levels to malondialdehyde acetaldehyde-adducts are associated with inflammatory mediators, obesity and type 2 diabetesAnnals of Medicine, 2013
- Porphyromonas gingivalis and disease‐related autoantibodies in individuals at increased risk of rheumatoid arthritisArthritis & Rheumatism, 2012
- Periodontal pathogen carriage, rather than periodontitis, determines the serum antibody levelsJournal of Clinical Periodontology, 2011
- Toll-like receptor 2 induces mucosal homing receptor expression and IgA production by human B cellsClinical Immunology, 2011
- 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiativeAnnals of the Rheumatic Diseases, 2010
- Definition of Metabolic SyndromeCirculation, 2004
- Multiserotype Enzyme-Linked Immunosorbent Assay as a Diagnostic Aid for Periodontitis in Large-Scale StudiesJournal of Clinical Microbiology, 2002